Clinical Trial Update: Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating patidegib gel at 2% and 4% vs vehicle to reduce GLI1 biomarker in sporadic nodular basal cell carcinomas; study completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• patidegib gel (patidegib)

Snippet

Sponsor: PellePharm, Inc. | Conditions: Basal Cell Carcinomas | Phase 2 | Status: COMPLETED | Results posted: 2019-01-04